Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAFV600E mutation treated with dabrafenib-trametinib: a case report

被引:2
|
作者
Martin-Soberon, M. C. [1 ]
Ruiz, S. [2 ]
De Velasco, G. [1 ]
Yarza, R. [1 ]
Carretero, A. [1 ]
Castellano, D. [1 ]
Sepulveda-Sanchez, J. M. [1 ]
机构
[1] Univ Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain
[2] Univ Hosp 12 Octubre, Nucl Med Dept, Madrid, Spain
关键词
Case report; Pneumatosis intestinalis (PI); Targeted therapies; Dabrafenib; Trametinib; Thyroid cancer; GAS;
D O I
10.1186/s13256-020-02581-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Pneumatosis intestinalis (PI) is a rare entity which refers to the presence of gas within the wall of the small bowel or colon which is a radiographic sign. The etiology and clinical presentation are variable. Patients with PI may present either with chronic mild non-specific symptoms or with acute abdominal pain with peritonitis. Some cases of intestinal pneumatosis have been reported as adverse events of new oncological treatments such as targeted therapies that are widely used in multiple tumors. Case presentation A 59-year-old caucasian female with radioactive iodine-refractory metastatic thyroid papillary carcinoma with BRAF(V600E) mutation was treated with dabrafenib and trametinib as a compassionate use. After 4 months treatment, positron emission tomography-computed tomography (PET-CT) showed PI. At the time of diagnosis, the patient was asymptomatic without signs of peritonitis. The initial treatment was conservative and no specific treatment for PI was needed. Unfortunately, after dabrafenib-trametinib withdrawal, the patient developed tumor progression with significant clinical worsening. Conclusions This case report is, in our knowledge, the first description of PI in a patient treated with dabrafenib-trametinib. Conservative treatment is feasible if there are no abdominal symptoms.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
    Rothenberg, S. Michael
    McFadden, David G.
    Palmer, Edwin L.
    Daniels, Gilbert H.
    Wirth, Lori J.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (05) : 1028 - 1035
  • [22] Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?
    Makboul, Rania
    Mostafa, Nadia M.
    El-Deek, Heba E. M.
    Aboulhagag, Noha A.
    Shehata, Mahmoud R.
    Abdelhafez, Yasser G.
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (05) : 416 - 425
  • [23] The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation
    Anekpuritanang, Tauangtham
    Uataya, Maythad
    Claimon, Apichaya
    Laokulrath, Natthawadee
    Pongsapich, Warut
    Pithuksurachai, Paveena
    [J]. ONCOTARGETS AND THERAPY, 2021, 14 : 3959 - 3969
  • [24] Correlation between BRAFV600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma
    Jiangqiao Geng
    Huanmin Wang
    Yuanhu Liu
    Jun Tai
    Yaqiong Jin
    Jie Zhang
    Lejian He
    Libing Fu
    Hong Qin
    Yingluan Song
    Jinzhu Su
    Aiying Zhang
    Xin Wen
    Yongli Guo
    Xin Ni
    [J]. Science China Life Sciences, 2017, 60 (07) : 729 - 738
  • [25] Accuracy and Reproducibility of Histologic Features Predictive of BRAFV600E Mutation in Papillary Thyroid Carcinoma
    Virk, R. K.
    Finkelstein, A.
    Prasad, A.
    Hui, P.
    Chhieng, D.
    Theoharis, C.
    Gibson, J.
    Roman, S.
    Prasad, M.
    [J]. MODERN PATHOLOGY, 2012, 25 : 150A - 151A
  • [26] Correlation between BRAFV600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma
    Jiangqiao Geng
    Huanmin Wang
    Yuanhu Liu
    Jun Tai
    Yaqiong Jin
    Jie Zhang
    Lejian He
    Libing Fu
    Hong Qin
    Yingluan Song
    Jinzhu Su
    Aiying Zhang
    Xin Wen
    Yongli Guo
    Xin Ni
    [J]. Science China Life Sciences, 2017, 60 : 729 - 738
  • [27] Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
    Lin, Yan-Yu
    Hsieh, Yu-Shan
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2023, 67 (02): : 172 - 178
  • [28] BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic
    Sykorova, V.
    Dvorakova, S.
    Ryska, A.
    Vcelak, J.
    Vaclavikova, E.
    Laco, J.
    Kodetova, D.
    Kodet, R.
    Cibula, A.
    Duskova, J.
    Hlobilkova, A.
    Astl, J.
    Vesely, D.
    Betka, J.
    Hoch, J.
    Smutny, S.
    Cap, J.
    Vlcek, P.
    Novak, Z.
    Bendlova, B.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2010, 33 (05) : 318 - 324
  • [29] Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAFV600E Mutation
    Lee, Seung Eun
    Hwang, Tae Sook
    Choi, Yoon-La
    Kim, Wook Youn
    Han, Hye Seung
    Lim, So Dug
    Kim, Wan-Seop
    Yoo, Young Bum
    Kim, Suk Kyeong
    [J]. THYROID, 2017, 27 (06) : 802 - 810
  • [30] BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic
    V. Sykorova
    S. Dvorakova
    A. Ryska
    J. Vcelak
    E. Vaclavikova
    J. Laco
    D. Kodetova
    R. Kodet
    A. Cibula
    J. Duskova
    A. Hlobilkova
    J. Astl
    D. Vesely
    J. Betka
    J. Hoch
    S. Smutny
    J. Cap
    P. Vlcek
    Z. Novak
    B. Bendlova
    [J]. Journal of Endocrinological Investigation, 2010, 33 : 318 - 324